Fumihiro Takahashi

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 900 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +6

Regulation of cell-cell contacts in developing Drosophila eyes by Dsrc41, a new, close relative of vertebrate c-src.

Fumihiro Takahashi, Satoshi Endo, Tetsuya Kojima et al. · Genes & Development · 1996 · 81 citations · Full text

Cell Lineage, Dsrc41-dependent Disorganization, Developmental Biology +15

Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

Fumihiro Takahashi, Koji Takei, Kikumi Tsuda et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 39 citations · Full text

Neurological Disorder, Post-hoc Analysis, Extension Study +20

Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis

Koji Takei, Fumihiro Takahashi, X. Shawn Liu et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 32 citations · Full text

Als Functional Rating, Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis +15

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 21 citations · Full text